Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 4, 2016, Pages 373-378

  Goyal, N A ^a   Cash, T M ^a   Alam, U ^a   Enam, S ^a   Tierney, P ^a   Araujo, N ^a   Mozaffar, F H ^a   Pestronk, A ^b,c   Mozaffar, T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; NT5C1A ANTIBODY; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; ANTIBODY; NT5C1A PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BULBAR PARALYSIS; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE MUSCLE; FEMALE; FORCED VITAL CAPACITY; HAND GRIP; HUMAN; INCLUSION BODY MYOSITIS; MALE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; STANDING; SYMPTOM; WALKER; WALKING; WHEELCHAIR; COMPLICATION; DEGLUTITION DISORDERS; DISABILITY; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RESPIRATION DISORDERS; SELF HELP DEVICE; SPINAL CORD DISEASES; TREATMENT OUTCOME; VITAL CAPACITY; WALKING DIFFICULTY;

5'-NUCLEOTIDASE; AGED; ANTIBODIES; CROSS-SECTIONAL STUDIES; DEGLUTITION DISORDERS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; MYOSITIS, INCLUSION BODY; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; RESPIRATION DISORDERS; SELF-HELP DEVICES; SPINAL CORD DISEASES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84930411103     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310008     Document Type: Article

References (41)

1. Cox F, Titulaer M, Sont J, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011;134:3167-75.
2. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84.
3. Engel W, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006;66:S20-9.
4. Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013;15:329.
5. Lotz B, Engel A, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-47.
6. Greenberg S. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012;25:630-9.
7. Karpati G, O'Ferrall E. Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol 2009;65:7-11.
8. Needham M, Mastaglia F. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31.
9. Dalakas M. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002;28:779-98.
10. Pruitt J, Showalter C, Engel A. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996;39:139-43.
11. Emslie-Smith A, Arahata K, Engel A. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-31.
12. Arahata K, Engel A. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
13. Arahata K, Engel A. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+cytotoxic and T8+suppressor cells. Ann Neurol 1988;23:493-9.
14. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988;23:64-72.
15. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005;26:373-80.
16. Salajegheh M, Pinkus J, Amato A, et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010;42:576-83.
17. Cupler E, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-93.
18. Salajegheh M, Lam T, Greenberg S. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011;6:e20266.
19. Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-18.
20. Pluk H, van Hoeve B, van Dooren S, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.
21. Greenberg SA. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014;50:488-92.
22. Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23:1044-55.
23. Pestronk A, Li F, Bieser K, et al. Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology 1994;44:1131-7.
24. Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991;41:357-62.
25. Jackson C, Barohn R, Gronseth G, et al. Muscle Study G. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008;37:473-6.
26. Beauchet O, Fantino B, Allali G, et al. Timed up and go test and risk of falls in older adults: a systematic review. J Nutr Health Aging 2011;15:933-8.
27. van der Ploeg A, Clemens P, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-406.
28. Querol L, Rojas-Garcia R, Casasnovas C, et al. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 2013;48:870-6.
29. Farrugia M, Harle H, Carmichael C, et al. The Oculobulbar Facial Respiratory score is a tool to assess bulbar function in myasthenia gravis patients. Muscle Nerve 2011;43:329-34.
30. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-42.
31. Hallert E, Husberg M, Skogh T. 28-Joint count disease activity score at 3months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatology 2011;50:1259-67.
32. Danon M, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci 1989;16:436-8.
33. Danon M, Friedman M. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 1992;15:115.
34. Verma A, Bradley W, Soule N, et al. Quantitative morphometric study of muscle in inclusion body myositis. J Neurol Sci 1992;112:192-8.
35. Wintzen A, Bots G, de Bakker H, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry 1988;51:1542-5.
36. Murata KY, Kouda K, Tajima F, et al. A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci 2012;33:765-70.
37. Littleton E, Man W, Holton J, et al. Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure. J Neurol Neurosurg Psychiatry 2002;72:650-2.
38. Cohen R, Lipper S, Dantzker D. Inclusion body myositis as a cause of respiratory failure. Chest 1993;104:975-7.
39. Voermans N, Vaneker M, Hengstman G, et al. Primary respiratory failure in inclusion body myositis. Neurology 2004;63:2191-2.
40. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001;124:2000-13.
41. Bradshaw E, Orihuela A, McArdel S, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-56.